Post-HSCT outcomes
| . | ALL, n = 27 . | AML, n = 33 . | ||
|---|---|---|---|---|
| Median time to, range (d), n | ||||
| Neutrophil recovery* | 14 (11-19) | 26 | 14 (9-30) | 33 |
| Platelet recovery* | 17 (9-19) | 23 | 16 (9-52) | 32 |
| Relapse, n (%) | 5 (19%) | 6 (18%) | ||
| Median time in d, range† | 198 (139-625) | 199 (49-1132) | ||
| Viral reactivation, n (%) | ||||
| Adenovirus | 5 (19%) | 4 (12%) | ||
| BK | 5 (19%) | 7 (21%) | ||
| CMV | 7 (26%) | 5 (15%) | ||
| HHV6 | 4 (15%) | 2 (6%) | ||
| EBV | 0 (0%) | 0 (0%) | ||
| GVHD | ||||
| Acute | ||||
| Any | 12 (46%) | 10 (30%) | ||
| Grade 3-4 | 6 (23%) | 2 (6%) | ||
| Chronic‡ | 6 (27%) | 8 (26%) | ||
| Limited | 3 (14%) | 5 (16%) | ||
| Extensive | 3 (14%)§ | 3 (9.7%)∥ | ||
| Treatment-related mortality | ||||
| Before day 100 | 3 (11%) | 1 (3%) | ||
| Overall | 4 (15%) | 4 (12%) | ||
| . | ALL, n = 27 . | AML, n = 33 . | ||
|---|---|---|---|---|
| Median time to, range (d), n | ||||
| Neutrophil recovery* | 14 (11-19) | 26 | 14 (9-30) | 33 |
| Platelet recovery* | 17 (9-19) | 23 | 16 (9-52) | 32 |
| Relapse, n (%) | 5 (19%) | 6 (18%) | ||
| Median time in d, range† | 198 (139-625) | 199 (49-1132) | ||
| Viral reactivation, n (%) | ||||
| Adenovirus | 5 (19%) | 4 (12%) | ||
| BK | 5 (19%) | 7 (21%) | ||
| CMV | 7 (26%) | 5 (15%) | ||
| HHV6 | 4 (15%) | 2 (6%) | ||
| EBV | 0 (0%) | 0 (0%) | ||
| GVHD | ||||
| Acute | ||||
| Any | 12 (46%) | 10 (30%) | ||
| Grade 3-4 | 6 (23%) | 2 (6%) | ||
| Chronic‡ | 6 (27%) | 8 (26%) | ||
| Limited | 3 (14%) | 5 (16%) | ||
| Extensive | 3 (14%)§ | 3 (9.7%)∥ | ||
| Treatment-related mortality | ||||
| Before day 100 | 3 (11%) | 1 (3%) | ||
| Overall | 4 (15%) | 4 (12%) | ||
Of those who engraft.
Of those who relapse.
Evaluable patients: ALL n = 22, AML n = 31.
Sites included: 1 patient with autoimmune hemolytic anemia, skin, and gut involvement, 1 with gut and lung, and 1 with skin and gut involvement that evolved from aGVHD.
Sites included: 1 patient with skin, ocular, and presumed lung involvement, 1 with bronchiolitis obliterans, and 1 with isolated skin involvement.